Analyser av SynAct Pharma

SynAct Pharma: Rights Issue Oversubscribed - Redeye

Redeye comments on SynAct’s successful rights issue.

Redeye initiates coverage of SynAct Pharma, a biotech company advancing a novel approach to controlling inflammation through resolution rath...